| 10.52 0.06 (0.57%) | 10-24 14:32 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 16.77 | 1-year : | 21.01 |
| Resists | First : | 14.36 | Second : | 17.98 |
| Pivot price | 11.83  |
|||
| Supports | First : | 8.5 | Second : | 7.07 |
| MAs | MA(5) : | 10.98 |
MA(20) : | 11.26 |
| MA(100) : | 8.7 |
MA(250) : | 8.8 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 17.9 |
D(3) : | 18.6 |
| RSI | RSI(14): 52.4 |
|||
| 52-week | High : | 17.98 | Low : | 0.44 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SNSE ] has closed above bottom band by 44.3%. Bollinger Bands are 158.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.99 - 11.05 | 11.05 - 11.12 |
| Low: | 9.85 - 9.91 | 9.91 - 9.98 |
| Close: | 10.33 - 10.45 | 10.45 - 10.58 |
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Fri, 17 Oct 2025
Sensei Biotherapeutics (SNSE) Reports Promising Results from Lat - GuruFocus
Fri, 17 Oct 2025
Sensei Biotherapeutics Reports New Clinical Results for Solnerstotug - TradingView
Fri, 17 Oct 2025
Sensei Biotherapeutics Reports New Clinical Results - GlobeNewswire
Fri, 17 Oct 2025
Sensei Biotherapeutics Reports 6‑Mo PFS 50% at 15 mg/kg | SNSE Stock News - Stock Titan
Wed, 03 Sep 2025
Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - The Manila Times
Wed, 03 Sep 2025
Cancer Therapeutics Developer Sensei Bio to Showcase Pipeline at Major Healthcare Conference - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 34.1 (%) |
| Held by Institutions | 5.5 (%) |
| Shares Short | 9 (K) |
| Shares Short P.Month | 10 (K) |
| EPS | -21.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 21.65 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36.8 % |
| Return on Equity (ttm) | -67.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -20.79 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -24 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -0.54 |
| PEG Ratio | 0 |
| Price to Book value | 0.52 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|